Floatz logo

mk-2206

Male Breast Cancer

National Cancer Institute (NCI)Small moleculePhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

10 Active assets in the Male Breast Cancer cohort.

Asset / SponsorPhaseRating
Irinotecan
University of California, Irvine
Phase 2BBB
Inno-206
National Cancer Institute (NCI)
Phase 2BBB
Cyclophosphamide
Wake Forest University Health Sciences
Phase 2BBB
FILGRASTIM
University of Washington
Phase 2BBB
Cediranib
University of Chicago
Phase 2BB

View all 50 →

Same molecule, other indications

mk-2206 is also rated in:

chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
BB
Indicative ·
64 / 100
View asset →
diffuse large B-cell lymphomaDormant
B
Indicative ·
60 / 100
View asset →
prostate cancerDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →